Minerva Neurosciences (NERV) Research & Development (2013 - 2026)
Minerva Neurosciences (NERV) posted Research & Development of $5.3 million for Q1 2026, up 141.76% on a QoQ basis from $2.2 million in Q4 2025, and up 285.7% year-over-year from $1.4 million in Q1 2025.
Minerva Neurosciences (NERV) Research & Development (2013 - 2026) Analysis & Trends
Minerva Neurosciences' Research & Development history runs 14 years deep, the most recent figure standing at $5.3 million for Q1 2026.
- Quarterly Research & Development rose 285.7% year-over-year to $5.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $9.7 million (up 6.14% YoY) and the FY2025 annual result came in at $5.8 million, down 51.6% from the prior year.
- Research & Development was $5.3 million for Q1 2026 at Minerva Neurosciences, up from $2.2 million in the prior quarter.
- Across five years, Research & Development topped out at $5.3 million in Q1 2026 and bottomed at $925377.0 in Q3 2025.
- A 5-year average of $3.0 million and a median of $2.7 million in 2023 frame the typical range for Research & Development.
- Annual changes were most pronounced in 2022 — Research & Development sank 82.98% — and 2026, when it surged 285.7%.
- Minerva Neurosciences' Research & Development stood at $3.2 million in 2022, then jumped by 47.99% to $4.7 million in 2023, then sank by 58.0% to $2.0 million in 2024, then grew by 9.62% to $2.2 million in 2025, then soared by 141.76% to $5.3 million in 2026.
- Business Quant data shows NERV's Research & Development at $5.3 million in Q1 2026, $2.2 million in Q4 2025, and $925377.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -17.94 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 541.22 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -2.31 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 961.60 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 1.54 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | 15.66 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 1.37 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 343.97 Mn |
| 10 | Minerva Neurosciences | 195.10 Mn | 195.10 Mn | - | 5.25 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 5.25 Mn |
| Dec 31, 2025 | 2.17 Mn |
| Sep 30, 2025 | 925,377.00 |
| Jun 30, 2025 | 1.30 Mn |
| Mar 31, 2025 | 1.36 Mn |
| Dec 31, 2024 | 1.98 Mn |
| Sep 30, 2024 | 1.89 Mn |
| Jun 30, 2024 | 3.86 Mn |
| Mar 31, 2024 | 4.17 Mn |
| Dec 31, 2023 | 4.72 Mn |
| Sep 30, 2023 | 3.44 Mn |
| Jun 30, 2023 | 1.89 Mn |
| Mar 31, 2023 | 2.65 Mn |
| Dec 31, 2022 | 3.19 Mn |
| Sep 30, 2022 | 2.37 Mn |
| Jun 30, 2022 | 4.13 Mn |
| Mar 31, 2022 | 4.96 Mn |
| Dec 31, 2021 | 18.75 Mn |
| Sep 30, 2021 | 4.51 Mn |
| Jun 30, 2021 | 5.52 Mn |